We currently have one approved medication on the market, as well as a number of late-stage and pre-clinical programs in our pipeline.
Adverse events should be reported. Please report to your country competent authority.
To report negative side effects of prescription drugs to the FDA, visit www.fda.gov/medwatch, or call 1-800-FDA-1088 (1-800-332-1088).
If you are a UK health care professional, reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to Immunocore, through the channels below.
United States:
medical.information@immunocore.com
844-IMMUNO1
Europe/Rest of World:
medinfo.eu@immunocore.com
+442076645100 (European local toll)
+00 800-74451111 (toll-free)
KIMMTRAK in the United States
KIMMTRAK (tebentafusp-tebn)
(Injection for Intravenous Use 100 mcg/0.5 mL)
KIMMTRAK in the United Kingdom
KIMMTRAK (tebentafusp)
(Concentrate for Solution for Infusion 200 mcg/mL)
KIMMTRAK in Europe
KIMMTRAK (tebentafusp)
(Concentrate for Solution for Infusion 100 mcg/0.5 mL)
KIMMTRAK in Switzerland
KIMMTRAK (tebentafusp)
(Concentrate for Solution for Infusion 100mcg/0.5mL)